chevron_leftBack
As of 24 April 2025, Ipsen S.A. has a market cap of $8.82B USD, ranking #1879 globally and #46 in France. It ranks #164 in the Healthcare sector, and #25 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$8.82BUSD
7.78B EUR
Enterprise Value
$8.64BUSD
7.62B EUR
Revenue (TTM)
$4.05BUSD
3.57B EUR
EBITDA (TTM)
$1.35BUSD
1.19B EUR
Net Income (TTM)
$391.99MUSD
345.9M EUR
EBITDA Margin
33%
Profit Margin
9.7%
PE Ratio
22.2
Company Profile
Country (HQ)
Sector
Healthcare
CEO
David Loew
open_in_new
Employees
5,358
Founded
1929
Website
ipsen.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.9% | -0.1% | -15% | -20% | -18% | -16% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
IPN
Ipsen SA
ISIN: FR0010259150
Shares Out.:
Shares Outstanding:
82.709M1
Shares Float:
34.75M2
|
94.70 EUR | |
|
0MH6
Ipsen SA
ISIN: FR0010259150
|
90.70 EUR | |
|
I7G
Ipsen SA
ISIN: FR0010259150
|
92.85 EUR | |
|
IPN
(IPN/N)
Ipsen SA
ISIN: FR0010259150
|
1.94K MXN | |
|
IPSEF
Ipsen SA
ISIN: FR0010259150
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
103.50 USD | |
|
IPSEY
Ipsen SA ADR
ISIN: US4626292050
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
27.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Ipsen S.A.
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
